HEMOSTEMIX
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors.
HEMOSTEMIX
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2006-01-01
Address:
Blackfalds, Alberta, Canada
Country:
Canada
Website Url:
http://www.hemostemix.com
Total Employee:
1+
Status:
Active
Contact:
403 471 6665
Email Addresses:
[email protected]
Total Funding:
11.26 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Abivax
Abivax is a pioneering biotech company.
Origin
Origin is a privately held, clinical-stage biotechnology company.
ArsenalBio
ArsenalBio is a programmable cell therapy company that offers advanced CAR T-cell therapies for solid tumors.
Atavistik Bio
Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Atom Bioscience & Pharmaceutical
Atom Bioscience is a clinical-stage biotechnology company.
Biorem Inc.
Biorem is a pioneer environmental biotechnology company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Cardurion Pharmaceuticals
Cardurion is a Boston-based cardiovascular biotechnology company
Cellenkos
Cellenkos is a clinical stage biotech company.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
EpicentRx Inc
EpicentRx Inc is a clinical-stage immuno-oncology company.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
IconOVir Bio
IconOVir Bio is a preclinical-stage biotechnology company.
ImmuneID
ImmuneID is a precision immunology company.
Immunicom
Immunicom is a biotechnology company.
IMV
IMV is a clinical-stage immuno-oncology company.
January Therapeutics
January Therapeutics is a San Diego-based biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
MaveriX Oncology
MaveriX Oncology is a globally-orientated biotechnology company.
Nano Cures
Nano Cures is clinical-stage biotechnology and infectious disease immunity platform company.
NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Oerth Bio
Oerth Bio is a agriculture-focused biotech firm.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Opthea
Opthea Limited is a public Australian biotechnology company .
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
People Corporation
People Corporation is publicly-traded on the TSX Venture Exchange under the symbol PEO.
Qualigen
Qualigen is a biotechnology company.
Relief Therapeutics
Relief Therapeutics is a clinical stage biotechnology company.
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SomaGenics
SomaGenics is a privately held biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Turnstone Biologics
Turnstone Biologics is a privately-held clinical stage biotech company.
Current Employees Featured
Founder
Stock Details
Investors List
Wood Capital
Wood Capital investment in Post-IPO Debt - Hemostemix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-16 | Hemostemix Announces Rick Groome as Special Advisor to The CEO |
Official Site Inspections
http://www.hemostemix.com Semrush global rank: 7.74 M Semrush visits lastest month: 437
- Host name: host9a.ionblade.com
- IP address: 135.148.50.237
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Hemostemix"
Stem Cell Therapy for CLI - Hemostemix
Hemostemix is an autologous (patient’s own) stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell …See details»
Hemostemix - Crunchbase Company Profile & Funding
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell …See details»
Get in touch with us at Hemostemix
Have any questions? Get in touch with us. Thomas A. Smeenk, BA President & CEO, Co-Founder Hemostemix Inc. TSXV:HEM 707 7th Ave. SW, Suite 1150 Calgary, AB T2P 3H6See details»
Hemostemix Inc.: Contact Details and Business Profile
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by …See details»
Hemostemix Inc. - LinkedIn
Hemostemix Inc. | 821 followers on LinkedIn. Clinical-stage biotech company focused on developing & commercializing stem cell therapies to treat ischemic diseases. | Hemostemix is …See details»
Hemostemix Inc. (TSXV: HEM) Company Profile & Overview
Nov 7, 2024 Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina …See details»
Hemostemix Inc. (HMTXF) Company Profile & Overview - Stock …
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead …See details»
Hemostemix Company Profile - Craft
Hemostemix is a biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP-01, its clinical-stage …See details»
Hemostemix
HemostemixSee details»
Hemostemix - Overview, News & Similar companies | ZoomInfo.com
Oct 22, 2023 Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease Calgary, Alberta--(Newsfile Corp. - …See details»
Company Hemostemix Inc. - MarketScreener.com
Nov 25, 2019 Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Companyâ s principal business is to develop, manufacture and commercialize blood-derived …See details»
Hemostemix - Products, Competitors, Financials, Employees, …
Jan 11, 2014 Hemostemix is an autologous stem cell therapeutics company focused on the development and commercialization of cell therapies for medical conditions related to …See details»
Hemostemix Inc. | Autologous Stem Cell Therapy Company - NAI …
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing …See details»
Hemostemix - Company Profile & Staff Directory - ContactOut
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by …See details»
Hemostemix Announces the Incorporation of Hemostemix Quebec …
Aug 29, 2023 Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix …See details»
Hemostemix Joins Centre for Commercialization of Regenerative …
May 5, 2014 Hemostemix is the newest member of the Centre for Commercialization of Regenerative Medicine’s (CCRM) industry consortium. CCRM will provide critical support to …See details»
Hemostemix Announces Letter of Commitment, Non-Dilutive …
Jan 19, 2023 The Letter of Commitment confirms that the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a ...See details»
Hemostemix. The Canadian Biotech that Could Change
Sep 11, 2021 Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood …See details»
Hemostemix Announces $2,725,982 Update to Second Closing
4 days ago About Hemostemix. Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the …See details»
Stay Up To Date With News About Hemostemix
Hemostemix has received a $250,000 Letter of Commitment. Hemostemix, an autologous stem cell therapy company, has received a $250,000 letter of commitment for funding from the …See details»